These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34277309)

  • 1. Thrombocytopenia in Chronic Liver Disease: Challenges and Treatment Strategies.
    Desai S; Subramanian A
    Cureus; 2021 Jul; 13(7):e16342. PubMed ID: 34277309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.
    Miller JB; Figueroa EJ; Haug RM; Shah NL
    Gastroenterol Hepatol (N Y); 2019 Jun; 15(6):326-332. PubMed ID: 31391802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
    Abdela J
    Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
    Xu H; Cai R
    Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
    [No Abstract]   [Full Text] [Related]  

  • 8. The Effect of Transjugular Intrahepatic Portosystemic Shunt on Platelet Counts in Patients With Liver Cirrhosis.
    Massoud OI; Zein NN
    Gastroenterol Hepatol (N Y); 2017 May; 13(5):286-291. PubMed ID: 28656025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombocytopenia associated with chronic liver disease.
    Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
    J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiology of thrombocytopenia in chronic liver disease.
    Mitchell O; Feldman DM; Diakow M; Sigal SH
    Hepat Med; 2016; 8():39-50. PubMed ID: 27186144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
    Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
    J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?
    Peck-Radosavljevic M; Zacherl J; Meng YG; Pidlich J; Lipinski E; Längle F; Steininger R; Mühlbacher F; Gangl A
    J Hepatol; 1997 Jul; 27(1):127-31. PubMed ID: 9252085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombocytopenia and liver disease: pathophysiology and periprocedural management.
    Lim HI; Cuker A
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):296-302. PubMed ID: 36485111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
    Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
    BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis.
    Karasu Z; Gurakar A; Kerwin B; Hulagu S; Jazzar A; McFadden R; Nour B; Sebastian A; Cassidy F; Stokes K; Van Thiel DH; Wright H
    Dig Dis Sci; 2000 Oct; 45(10):1971-6. PubMed ID: 11117569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of thrombocytopenia due to liver cirrhosis: a review.
    Hayashi H; Beppu T; Shirabe K; Maehara Y; Baba H
    World J Gastroenterol; 2014 Mar; 20(10):2595-605. PubMed ID: 24627595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombocytopenia in Chronic Liver Disease: New Management Strategies.
    Nilles KM; Flamm SL
    Clin Liver Dis; 2020 Aug; 24(3):437-451. PubMed ID: 32620282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease.
    Elsaid MI; Rustgi VK; Loo N; Aggarwal K; Li-McLeod J; Niu X; Poordad F
    J Med Econ; 2020 Apr; 23(4):378-385. PubMed ID: 31777291
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.